Pharsight

Combigan patents expiration

COMBIGAN's oppositions filed in EPO
COMBIGAN Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7642258 ABBVIE INC Combination of brimonidine and timolol for topical ophthalmic use
Apr, 2022

(1 year, 11 months ago)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7320976 ABBVIE INC Combination of brimonidine and timolol for topical ophthalmic use
Apr, 2022

(1 year, 11 months ago)

US8133890 ABBVIE INC Combination of brimonidine and timolol for topical ophthalmic use
Apr, 2022

(1 year, 11 months ago)

US9770453 ABBVIE INC Combination of brimonidine and timolol for topical ophthalmic use
Apr, 2022

(1 year, 11 months ago)

US9907801 ABBVIE INC Combination of brimonidine and timolol for topical ophthalmic use
Apr, 2022

(1 year, 11 months ago)

US8354409 ABBVIE INC Combination of brimonidine and timolol for topical ophthalmic use
Apr, 2022

(1 year, 11 months ago)

US8748425 ABBVIE INC Combination of brimonidine and timolol for topical ophthalmic use
Apr, 2022

(1 year, 11 months ago)

US9907802 ABBVIE INC Combination of brimonidine and timolol for topical ophthalmic use
Apr, 2022

(1 year, 11 months ago)

US9474751 ABBVIE INC Combination of brimonidine and timolol for topical ophthalmic use
Apr, 2022

(1 year, 11 months ago)

US7030149 ABBVIE INC Combination of brimonidine timolol for topical ophthalmic use
Apr, 2022

(1 year, 11 months ago)

US7323463 ABBVIE INC Combination of brimonidine and timolol for topical ophthalmic use
Jan, 2023

(1 year, 2 months ago)

Combigan is owned by Abbvie Inc.

Combigan contains Brimonidine Tartrate; Timolol Maleate.

Combigan has a total of 11 drug patents out of which 11 drug patents have expired.

Expired drug patents of Combigan are:

  • US7320976
  • US8133890
  • US9770453
  • US9907801
  • US8354409
  • US8748425
  • US9907802
  • US9474751
  • US7030149
  • US7323463
  • US7642258

Combigan was authorised for market use on 30 October, 2007.

Combigan is available in solution/drops;ophthalmic dosage forms.

Combigan can be used as reduction of elevated intraocular pressure (iop) in patients with glaucoma or ocular hypertension who require adjunctive or replacement therapy due to inadequately controlled iop. dose is one drop of combigan in the affected eye twice daily, reduction of elevated intraocular pressure in patients with glaucoma or ocular hypertension, reduction of elevated intraocular pressure (iop) in patients with glaucoma or ocular hypertension, with comparable efficacy, and a reduction in specified adverse events, compared to brimonidine 0.2% tid, reduction of intraocular pressure in patients with elevated intraocular pressure or glaucoma, reduction of elevated intraocular pressure in patients with glaucoma or ocular hypertension who require adjunctive or replacement therapy due to inadequately controlled iop, reduction of elevated intraocular pressure (iop) in patients with glaucoma or ocular hypertension, with a reduction in specified adverse events, compared to brimonidine 0.2% tid, reduction of elevated intraocular pressure (iop) in patients with glaucoma or ocular hypertension, with comparable efficacy to brimonidine 0.2% tid, reduction of elevated intraocular pressure.

The generics of Combigan are possible to be released after 19 January, 2023.

Drugs and Companies using BRIMONIDINE TARTRATE; TIMOLOL MALEATE ingredient

Market Authorisation Date: 30 October, 2007

Treatment: Reduction of elevated intraocular pressure (iop) in patients with glaucoma or ocular hypertension who require adjunctive or replacement therapy due to inadequately controlled iop. dose is one drop of ...

Dosage: SOLUTION/DROPS;OPHTHALMIC

How can I launch a generic of COMBIGAN before it's drug patent expiration?
More Information on Dosage

COMBIGAN family patents

Family Patents